334 related articles for article (PubMed ID: 26177051)
21. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
Blagosklonny MV
Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia and gerosuppression: the mTOR saga continues.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2012 Nov; 11(21):3926-31. PubMed ID: 22987149
[TBL] [Abstract][Full Text] [Related]
24. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
25. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential.
Demidenko ZN; Blagosklonny MV
Aging (Albany NY); 2009 Dec; 1(12):1008-16. PubMed ID: 20157583
[TBL] [Abstract][Full Text] [Related]
26. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.
Liu Q; Kirubakaran S; Hur W; Niepel M; Westover K; Thoreen CC; Wang J; Ni J; Patricelli MP; Vogel K; Riddle S; Waller DL; Traynor R; Sanda T; Zhao Z; Kang SA; Zhao J; Look AT; Sorger PK; Sabatini DM; Gray NS
J Biol Chem; 2012 Mar; 287(13):9742-9752. PubMed ID: 22223645
[TBL] [Abstract][Full Text] [Related]
27. Gerosuppression in confluent cells.
Leontieva OV; Blagosklonny MV
Aging (Albany NY); 2014 Dec; 6(12):1010-8. PubMed ID: 25585637
[TBL] [Abstract][Full Text] [Related]
28. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
29. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
30. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8832-7. PubMed ID: 24889617
[TBL] [Abstract][Full Text] [Related]
31. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Waetzig R; Matthes M; Leister J; Penkivech G; Heise T; Corbacioglu S; Sommer G
Int J Med Sci; 2021; 18(1):137-149. PubMed ID: 33390782
[TBL] [Abstract][Full Text] [Related]
32. Growth stimulation leads to cellular senescence when the cell cycle is blocked.
Demidenko ZN; Blagosklonny MV
Cell Cycle; 2008 Nov; 7(21):3355-61. PubMed ID: 18948731
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin decelerates cellular senescence.
Demidenko ZN; Zubova SG; Bukreeva EI; Pospelov VA; Pospelova TV; Blagosklonny MV
Cell Cycle; 2009 Jun; 8(12):1888-95. PubMed ID: 19471117
[TBL] [Abstract][Full Text] [Related]
34. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
Leontieva OV; Blagosklonny MV
Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
[TBL] [Abstract][Full Text] [Related]
35. Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model.
Salama M; Elhussiny M; Magdy A; Omran AG; Alsayed A; Ashry R; Mohamed W
Metab Brain Dis; 2018 Apr; 33(2):583-587. PubMed ID: 29080085
[TBL] [Abstract][Full Text] [Related]
36. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
37. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
38. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
[TBL] [Abstract][Full Text] [Related]
39. Suppression of replicative senescence by rapamycin in rodent embryonic cells.
Pospelova TV; Leontieva OV; Bykova TV; Zubova SG; Pospelov VA; Blagosklonny MV
Cell Cycle; 2012 Jun; 11(12):2402-7. PubMed ID: 22672902
[TBL] [Abstract][Full Text] [Related]
40. While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts.
Leontieva OV; Blagosklonny MV
Oncotarget; 2017 Dec; 8(65):109848-109856. PubMed ID: 29312653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
